7 results about "Dexibuprofen" patented technology

The invention provides a dexibuprofen preparation process. The dexibuprofen preparation process comprises the following steps: (1) splitting: adding ibuprofen and meglumine into a solvent, dissolving, heating to form salt, cooling to crystallize, filtering and drying to obtain dexibuprofen meglumine salt; (2) dissociation: adding the dexibuprofen meglumine salt into a solvent, dissociating under an alkaline condition, filtering to remove meglumine, crystallizing the solution, and filtering to obtain a dexibuprofen crude product; and (3) crystallizing dexibuprofen: adding a solvent, heating and dissolving, cooling, separating out a solid, filtering, crushing or granulating, and drying to obtain dexibuprofen with different particle sizes. The dexibuprofen preparation process provided by the invention is high in production efficiency and conversion efficiency, and the prepared product is high in purity and few in impurities. The dexibuprofen product with the crystal form consistent with that of an original product can be stably prepared, the granularity is uniform, and the requirement of the dexibuprofen preparation on the granularity can be met after the dexibuprofen product is crushed.

The invention provides a dexibuprofen chewable tablet preparation composition of a unit preparation, and the preparation composition seeks a balance between taste masking and infusion or between taste masking and tablet weight reduction to a pharmaceutically acceptable degree from selection of preparation auxiliary materials. Therefore, the low-tablet-weight dexibuprofen chewable tablet which is appropriate in mouth feel and free of a melting phenomenon on the surface is prepared.

The invention relates to a crystal form compound of dexibuprofen arginine, which has diffraction peaks at diffraction angles 2 theta of 6.0 + / -0.2 degrees, 16.8 + / -0.2 degrees, 17.9 + / -0.2 degrees, 19.1 + / -0.2 degrees, 21.5 + / -0.2 degrees, 23.4 + / -0.2 degrees and 24.1 + / -0.2 degrees in an X-ray powder diffraction pattern measured under Cu-K alpha radiation. The invention also relates to a preparation method of the crystal-form compound and a pharmaceutical composition containing the crystal-form compound.

The invention relates to a dexibuprofen true solution as well as a preparation method and application thereof. Specifically, the invention relates to a dexibuprofen true solution oral drop, which is prepared from 5 mg to 400 mg / ml of dexibuprofen and a cosolvent, the weight ratio of the dexibuprofen to the cosolvent is about 1.5: 1. Optionally, the dexibuprofen solution is subpackaged in a single-dose or multi-dose package. The prescription is the optimal prescription determined on the basis of a large number of optimized prescriptions, the design is reasonable, and the process is suitable for industrial production. The product is controllable in quality and stable in performance.

The invention discloses a preparation method of a switch controlled-release dexibuprofen emulsion in the field of medicines. The preparation method comprises the following steps: dissolving dexibuprofen in HFE-7200 to serve as an inner phase; silicone oil is used as an external phase; mixing and fusing two surfactants A and B into a PBS (Phosphate Buffer Solution) as a continuous phase; the type A surfactant is one of Tween-20 and Tween-80, and the type B surfactant is one of Tween-20 and Tween-80; the type B is a surfactant which is one of F68, F127 and PEG40S (Polyethylene Glycol 40S); the inner phase and the outer phase are mixed to form an oil phase; mixing the continuous phase and the oil phase, and oscillating to form a closed IBU drug-loaded emulsion; and a B-type surfactant is additionally added, so that the rapidly-released'open 'type IBU drug-loaded emulsion can be formed. According to the present invention, the drug is subjected to on-off release through the carrier, such that the problems of specific odor and spicy taste of IBU are solved, the stomach stimulation and other side effects caused by rapid release are reduced, and the emulsion drug loading structure system has characteristics of long-term stability, easy controlled release and high drug loading rate.

The dexibuprofen injection composition provided by the invention is more stable, and the inventor establishes a specific molar ratio of arginine to dexibuprofen to control the pH value of the injection within a specific range, so that the problem of clarity of the dexibuprofen injection is solved, the yield is greatly improved, and the requirements of industrial mass production are met.

The present disclosure provides novel methods for treatment of patients with autophagy diseases by administering a prodrug of dexibuprofen, such as but not limited to dexibuprofen dimethylamino ethyl ester (mDex) or a pharmaceutically acceptable salt thereof and compositions comprising the same.